1 – 10 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
(
- Contribution to journal › Article
-
Mark
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
(
- Contribution to journal › Article
-
Mark
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
(
- Contribution to journal › Article
- 2022
-
Mark
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(
- Contribution to journal › Scientific review
-
Mark
SELNET clinical practice guidelines for bone sarcoma
(
- Contribution to journal › Article
-
Mark
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
(
- Contribution to journal › Article
-
Mark
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes : Pooled Analysis of Population-Based Studies
(
- Contribution to journal › Article
-
Mark
Fibrinogen-like protein 2 in gastrointestinal stromal tumour
(
- Contribution to journal › Article
- 2021
-
Mark
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy : Results from the EUROpean Bone Over 40 Sarcoma Study
(
- Contribution to journal › Article
-
Mark
Adjuvant imatinib for GIST : duration likely matters
(
- Contribution to journal › Debate/Note/Editorial